Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (261-270 of 706) with videos related to

Pageof 71
Sort By:
American Heart Journal|August 13, 2011
Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD)Hector M Medina, Christopher P Cannon, Xin Zhao, et al.
Rheumatology (Oxford, England)|February 19, 2009
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)Bernard Combe, Gary Swergold, James McLay, et al.
Chest|September 24, 2004
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyVenu Menon, Robert A Harrington, Judith S Hochman, et al.
European Journal of Heart Failure|April 22, 2009
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL programHenry Krum, Sean P Curtis, Amarjot Kaur, et al.
The American Journal of Cardiology|October 10, 2002
Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classificationBenjamin M Scirica, Christopher P Cannon, Carolyn H McCabe, et al.
American Heart Journal|October 3, 2002
Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapyBrad G Angeja, James de Lemos, Sabina A Murphy, et al.
Journal of the American College of Cardiology|October 15, 2011
Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care?Apurva A Motivala, Christopher P Cannon, Vankeepuram S Srinivas, et al.
The American Journal of Cardiology|November 30, 2004
Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarctionMinang P Turakhia, Sabina A Murphy, Tina L Pinto, et al.
JAMA|November 26, 2009
Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomesDharam J Kumbhani, Christopher P Cannon, Gregg C Fonarow, et al.
The American Journal of Cardiology|July 29, 2017
Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II)Mahfouz El Shahawy, Christopher P Cannon, Dirk J Blom, et al.
Pageof 71

Showing results (261-270 of 706) with videos related to

Sort By:
Pageof 71
American Heart Journal|August 13, 2011
Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD)Hector M Medina, Christopher P Cannon, Xin Zhao, et al.
Rheumatology (Oxford, England)|February 19, 2009
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)Bernard Combe, Gary Swergold, James McLay, et al.
Chest|September 24, 2004
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyVenu Menon, Robert A Harrington, Judith S Hochman, et al.
European Journal of Heart Failure|April 22, 2009
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL programHenry Krum, Sean P Curtis, Amarjot Kaur, et al.
The American Journal of Cardiology|October 10, 2002
Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classificationBenjamin M Scirica, Christopher P Cannon, Carolyn H McCabe, et al.
American Heart Journal|October 3, 2002
Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapyBrad G Angeja, James de Lemos, Sabina A Murphy, et al.
Journal of the American College of Cardiology|October 15, 2011
Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care?Apurva A Motivala, Christopher P Cannon, Vankeepuram S Srinivas, et al.
The American Journal of Cardiology|November 30, 2004
Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarctionMinang P Turakhia, Sabina A Murphy, Tina L Pinto, et al.
JAMA|November 26, 2009
Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomesDharam J Kumbhani, Christopher P Cannon, Gregg C Fonarow, et al.
The American Journal of Cardiology|July 29, 2017
Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II)Mahfouz El Shahawy, Christopher P Cannon, Dirk J Blom, et al.
Pageof 71